A clinical study using Evenamide (orally taken new drug with out masking its strenghth) to determine its safety, tolerability and efficacy in patients with treatment resistant schizophrenia, not befitting adequately from their current antipsychotic medication - Trial SLCTR_2020_023
Access comprehensive clinical trial information for SLCTR_2020_023 through Pure Global AI's free database. This Phase 2 trial is sponsored by Dr Ravi Anand and is currently Completed. The study focuses on schizophrenia.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to Sri Lanka Clinical Trials Registry data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Free Database
Powered by Pure Global AI
840K+ Trials
SLCTR_2020_023
Phase 2
Completed
Trial Details
Sri Lanka Clinical Trials Registry • SLCTR_2020_023
A clinical study using Evenamide (orally taken new drug with out masking its strenghth) to determine its safety, tolerability and efficacy in patients with treatment resistant schizophrenia, not befitting adequately from their current antipsychotic medication
A pilot, open-label, rater-blinded, randomized, parallel-group, multi-center study to evaluate the safety, tolerability and preliminary efficacy of three add-on fixed doses of evenamide in patients with treatment-resistant schizophrenia (TRS) not responding adequately to their stable, therapeutically active dose of a single antipsychotic medication
Study Focus
Interventional
Sponsor & Location
Dr Ravi Anand
India
Timeline & Enrollment
Phase 2
Feb 12, 2021
N/A
ICD-10 Classifications
Schizophrenia
Simple schizophrenia
Schizophrenia, unspecified
Other schizophrenia
Paranoid schizophrenia
Data Source
Sri Lanka Clinical Trials Registry
SLCTR_2020_023
Non-Device Trial